- Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.All claims unpatentablePTAB · Jan 9, 2024 · IPR2022-01226 · APJ John G New · IPR · Final written decision
Claims 1–9, 34–39, 41–43, and 45 are unpatentable as anticipated by Dixon; the Board did not reach the remaining grounds.
RulingsFinal written decision- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)UnpatentableUnpatentable
“inter partes review are anticipated by Dixon and therefore unpatentable (Ground 1). Because we reach this conclusion, we do not reach Petitioner’s contentions that the claims are obvious on the basis of Ground 5. Nor does our analysis rely upon, or cite to, Exhibit 1058. We consequently dismiss as moot Patent Owner’s motion to exclude Exhibit 1058.” slip op. at 24
- ExcludeMotion to exclude, grantedMotion to exclude, deniedMixed
“challenged claims are thus anticipated, we do not reach the additional Grounds 2–7 proposed in the Petition. Furthermore, Petitioner’s Motion to Exclude Evidence is granted-in-part, denied-in-part and dismissed-in-part. Patent Owner’s Motion to Exclude Evidence is denied-in-part and dismissed-in-part.” slip op. at 92
Patent outcomesUS 10,888,601 unpatentable§ 102 anticipationcites PhillipsPatents in suitUS 10,888,601 - Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.All claims unpatentablePTAB · Jan 9, 2024 · IPR2023-00532 · APJ John G New · IPR · Final written decision
Claims 1, 3–11, 13, 14, 16–24, and 26 are unpatentable as anticipated by Dixon; the Board did not reach Grounds 2–6.
RulingsFinal written decision- Claim Construction › Intrinsic evidence (Phillips canons) › Preamble limiting or notPreamble limitingDecided for patent owner
“Decision. See Ex. 3001, 12–23. As an initial matter, we are not persuaded by Patent Owner’s reliance on Sanofi and Eli Lilly. See PO Resp. 9. In Sanofi, a non-precedential decision, the Federal Circuit held that the preamble to the claims at issue, reciting “[a] method of increasing survival comprising administering to a patient in need thereof” was limiting upon the claims, in conformance with the court’s prior decisions in Jansen v. Rexall Sundown, Inc., 342 F.3d 1329, 1333 (Fed. Cir. 2003) and Rapoport v. Dement, 254 F.3d 1053 (Fed. Cir. 2001). Sanofi, 757 F. App’x at 992–93. Furthermore, the court held that, because the preamble was limiting, and recited a “method of increasing survival” the proposed claims would now clearly require “increasing survival.” Id. at 994. The preamble to claim 1 of the ’681 patent, however, recites no such “increase” with respect to efficacy, but merely recites “A method for treating an angiogenic eye disorder in a patient,” and the remainder of the claim requires no specific efficacy requirement. Nor does Eli Lilly support Patent Owner’s position. In Eli Lilly, the court upheld the Board’s conclusion that the preamble reciting “a method for treating headache in an individual” was limiting upon the claims. Eli Lilly, 8 F.4th at 1343. However, it noted, in upholding the Board’s conclusion, the Board also “found that while the claims encompass a clinical result, they do not require such a result.” Id. (emphasis added). We also find that the similar language of the preamble to challenged claim 1 of the ’681 patent, although encompassing clinical efficacy, does not require it, let alone a “high degree of efficacy.”” slip op. at 33
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed board ownDecided for patent owner
“the preamble’s recitation of a “method for treating” requires a high level of efficacy. In the -00881 Decision, the Board rejected Patent Owner’s similar argument because it required improperly importing limitations into the claims. See Ex. 3001, 22. Specifically, the Board found that: [W]hen the Specification explains that “[t]he amount of VEGF antagonist administered to the patient in each dose is, in most cases, a therapeutically effective amount,” and discloses that “a therapeutically effective amount can be from about 0.05 mg to about 5 mg,” we find that a POSA would have understood that any dosage amount within that range administered according to the invention may, in some cases, result in a detectable improvement in “one or more symptoms or indicia of an angiogenic eye disorder,” or be one that “inhibits, prevents, lessens or delays the progression of an angiogenic eye disorder,” or it may not. In either event, the VEGF antagonist would have been administered for the purpose of treating the eye disorder. In other words, the method of treating the patient with the eye disorder is performed upon administration of the VEGF antagonist to the patient for the purpose of achieving an improvement or beneficial effect in the eye disorder, regardless whether the dosage amount administered actually achieves that intended result. Id. at 21–22 (citation omitted). Furthermore, the Board found that: Patent Owner proposes that the claims require not only achieving a therapeutically effective result, but more specifically, achieving a “high level of efficacy that was noninferior to the standard of care by the time the patent was filed in 2011.” In the Sur-reply, Patent Owner describes a “highly effective treatment for angiogenic eye disorders” as “one that is on par to Lucentis or off-label Avastin and can produce visual acuity gains, not just slow vision losses.” The Specification refers to “a high level of efficacy” in one instance, i.e., in the “Background” section. The Specification does not describe there, or elsewhere that “treating,” in the context of the claims or in the art, requires achieving a “high level of efficacy” or providing results “on par to Lucentis or off-label Avastin.” Id. at 22 (citations omitted). We adopt the same reasoning here, and find that, for the purposes of this Decision, the evidence of record and the Specification support construing the preamble’s recitation of a “method for treating a patient with an angiogenic eye disorder” as meaning administering a compound, i.e., the recited VEGF antagonist, to such patient for the purpose of improving or providing a beneficial effect in their angiogenic eye disorder. We find that, as in Eli Lilly, although the claims “encompass a clinical result, they do not require such a result.” Eli Lilly, 8 F.4th at 1343. We consequently reject” slip op. at 35
- Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed petitioner constructionDecided for petitioner
“The terms “initial dose,” “secondary doses,” and “tertiary doses,” refer to the temporal sequence of administration of the VEGF antagonist Thus, the “initial dose” is the dose which is administered at the beginning of the treatment regimen (also referred to as the “baseline dose”) ; the “secondary doses” are the doses which are administered after the initial dose; and the “tertiary doses” are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of dosing regimens, but will generally differ from one another in terms of frequency of administration. Ex. 1001, col. 3 ll. 34–44. Petitioner also notes that the Specification further explains that “the immediately preceding dose” means “in a sequence of multiple administrations, the dose of VEGF antagonist which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.” Pet. 24 (citing Ex. 1001, col. 3, ll. 54–59; Ex. 1002 ¶¶ 44–45). We adopt Petitioner’s proposed construction of the claim terms “initial dose,” “secondary dose,” and “tertiary dose.” Petitioner proposes adoption of the definitions expressly set forth in the Specification of the ’681 patent, viz., that the initial dose is the dose “administered at the beginning of the treatment regimen,” and is followed by the secondary doses that are “administered after the initial dose,” and the tertiary doses are “administered after the secondary doses” and may be distinguished from the secondary doses “in terms of frequency of administration.” Ex. 1001, col. 3, ll. 36–44.” slip op. at 37
- Obviousness (§103) › Objective indicia / secondary considerationsNot reached
“As Petitioner states, Patent Owner relies upon these Exhibits as objective secondary evidence of non-obviousness. See, e.g., PO Resp. 65– 69. However, and as we explain below, because we find that the challenged claims are anticipated by Dixon, we do not reach Patent Owner’s arguments that the claims are non-obvious (Grounds 4–6) or its contentions regarding secondary considerations of non-obviousness. See Cohesive Techs., Inc. v. Waters Corp., 543 F.3d 1351, 1364 (Fed. Cir. 2008) (holding that “secondary considerations are not an element of a claim of anticipation”). Consequently, we dismiss Petitioner’s motion to dismiss the Financial Documents as moot.” slip op. at 10
Patent outcomesUS 10,130,681 unpatentableClaim construction§ 102 anticipation§ 103 obviousnesscites PhillipsPatents in suitUS 10,130,681 - Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.All claims unpatentablePTAB · Jan 9, 2024 · IPR2022-01225 · APJ John G New · IPR · Final written decision
Claims 1, 3–11, 13, 14, 16–24, and 26 are unpatentable as anticipated by Dixon; the Board did not reach the remaining grounds.
RulingsFinal written decision- Claim Construction › Intrinsic evidence (Phillips canons) › Preamble limiting or notPreamble limitingDecided for patent owner
“Here, the claims are directed to methods of administering, i.e., using, a VEGF antagonist for an intended purpose of “treating an angiogenic eye disorder in a patient.” The Specification repeatedly characterizes the method as one for treating angiogenic eye disorders in patients. Apart from the preamble, the independent claims do not elsewhere recite or indicate any other use for the method steps comprising the administration of a VEGF antagonist. Thus, we determine that the preamble sets forth the essence of the invention—treating an angiogenic eye disorder in a patient. Additionally, we find that the preamble provides antecedent basis for claim terms “the patient” recited in the body of each independent claim, and “angiogenic eye disorders” recited in dependent claims 6, 7, 18, and 20. Indeed, without the preamble, it would be unclear to whom the doses of VEGF are administered. Thus, …in view of the evidence of record, namely, the claim language and the written description of the ’338 patent, we find that the preambles of method claims 1 and 14 are limiting insofar as they require “treating an angiogenic eye disorder in a patient.” Id. at 17–18 (citations omitted). We adopt this same reasoning here and find that the preamble of claim 1 reciting “[a] method for treating an angiogenic eye disorder in a patient” is limiting.” slip op. at 34
- Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed petitioner constructionDecided for petitioner
“We adopt Petitioner’s proposed construction of the claim terms “initial dose,” “secondary dose,” and “tertiary dose.” Petitioner proposes adoption of the definitions expressly set forth in the Specification of the ’681 patent, viz., that the initial dose is the dose “administered at the beginning of the treatment regimen,” and is followed by the secondary doses that are “administered after the initial dose,” and the tertiary doses are “administered after the secondary doses” and may be distinguished from the secondary doses “in terms of frequency of administration.” Ex. 1001, col. 3, ll. 36–44.” slip op. at 37
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededDecided for petitioner
“If a claim limitation is directed to printed matter, the next step in the Praxair analysis is to determine whether the printed matter is functionally related to its “substrate.” Praxair, 890 F.3d at 1032. Printed matter that is functionally related to its substrate is given patentable weight. Id. (citing DiStefano, 808 F.3d at 850). However, “[w]here the printed matter is not functionally related to the substrate, the printed matter will not distinguish the invention from the prior art in terms of patentability.” Id. (quoting In re Ngai, 367 F.3d 1336, 1339 (Fed. Cir. 2004)). More specifically, printed matter is functionally related to its substrate when the language changes not mere thoughts or outcomes, but provides action steps that the method requires. See C R Bard Inc. v. AngioDynamics, Inc., 979 F.3d 1372, 1381 (Fed. Cir. 2020) (holding that the test for printed matter is whether it “merely informs people of the claimed information, or whether it instead interacts with the other elements of the claim to … cause a specific action in a claimed process.”); see also Bristol-Myers Squibb Co. v. Ben Venue Laboratories, Inc., 246 F.3d 1368, 1376 (Fed. Cir. 2001) (stating that language “is only a statement of purpose and intended result” where its “expression does not result in a manipulative difference in the steps of the claim”) (emphasis added).” slip op. at 46
- Skill levelSkill level petitioner adoptedDecided for petitioner
“A Person of Ordinary Skill in the Art Petitioner contends that a person of ordinary skill in the art would have: (1) knowledge regarding the diagnosis and treatment of angiogenic eye disorders, including the administration of therapies to treat said disorders; and (2) the ability to understand results and findings presented or published by others in the field. Pet. 28. Petitioner asserts that such a person would typically have an advanced degree, such as an M.D. or Ph.D. (or equivalent, or less education but considerable professional experience in the medical, biotechnological, or pharmaceutical field), with practical academic or medical experience in (i) developing treatments for angiogenic eye disorders, including through the use of VEGF antagonists, or (ii) treating of same, including through the use of VEGF antagonists. Id. at 28–29 (citing Ex. 1002 ¶¶ 27–29; Ex. 1003 ¶¶ 21–25). Patent Owner does not expressly contest this definition of a person of ordinary skill in the art in its Response. Because we find Petitioner’s definition to be consistent with the level of skill in the art (see, e.g., Exs. 1006, 1020), we adopt Petitioner’s definition.” slip op. at 52
Patent outcomesUS 10,130,681 unpatentableClaim construction§ 102 anticipation§ 103 obviousnesscites PhillipsPatents in suitUS 10,130,681 - PTAB · Dec 1, 2023 · PGR2022-00025 · APJ Susan L C Mitchell · PGR · Remand
The Board granted PGR of claims 1–19, finding claim 1 more likely than not anticipated by Grigoriadis and claims 1–19 more likely than not lacking written-description support.
RulingsRemand decision- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted
“Institution of post-grant review is authorized by statute only when “the information presented in the petition . . . demonstrate[s] that it is more likely than not that at least 1 of the claims challenged in the petition is unpatentable.” 35 U.S.C. § 324; see 37 C.F.R. § 42.4. Upon considering the Petition, Patent Owner Preliminary Response, and the cited evidence in light of the Director’s Decision, we conclude that Petitioner has satisfied its burden under 35 U.S.C. § 324 to show that it is more likely than not that at least 1 of the claims challenged in the Petition is unpatentable. Therefore, we grant institution of a post-grant review.” slip op. at 2
- Skill levelSkill level petitioner adoptedDecided for petitioner
“B. Person of Ordinary Skill in the Art Factual indicators of the level of ordinary skill in the art include “the various prior art approaches employed, the types of problems encountered in the art, the rapidity with which innovations are made, the sophistication of the technology involved, and the educational background of those actively working in the field.” Jacobson Bros., Inc. v. U.S., 512 F.2d 1065, 1071 (Ct. Cl. 1975); see also Orthopedic Equip. Co. v. U.S., 702 F.2d 1005, 1011 (Fed. Cir. 1983) (quoting with approval Jacobson Bros.).” slip op. at 7
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed board ownDecided for petitioner
“Independent claim 1 recites a method of treating CAH by reducing an A4 level “from baseline” after administering a CRF1 receptor antagonist to a CAH patient. See Ex. 1001, 47:51–48:5. The Specification expressly teaches that, with respect to the clinical phase 2 trial described in Example 4, “Patients will have overnight [pharmacokinetic/pharmacodynamics] PK/PD assessments performed at baseline, which include an [sic] pre-dose overnight assessment and a post-dose overnight assessment for PK/PD following administration of the first dose.” Ex. 1001, 41:55–59. This is the same quotation and clinical trial relied upon by Dr. Barnes in his Declaration, and is the only definition of a “baseline” in the ’201 patent. See Ex. 1037, 36–37. We note that placebos were evidently not employed in the phase 2 clinical study of Example 4.5 Given the sole exemplary description of “baseline” in Example 4 of the Specification, we construe the claim term reciting “reduced from baseline” as meaning “a reduction in A4 level compared to an A4 level measurement made prior to, and/or at the beginning of, administration of the drug.”” slip op. at 10
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)Reference is prior artInstituted
“A claim is unpatentable as anticipated under 35 U.S.C. § 102 only when “every element and limitation of the claim was previously described in a single prior art reference, either expressly or inherently, so as to place a person of ordinary skill in possession of the invention.” Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1082 (Fed. Cir. 2008). A reference may inherently anticipate if a claim limitation that is not expressly disclosed “is necessarily present, or inherent, in the single anticipating reference.” Verizon Servs. Corp. v. Cox Fibernet Va., Inc., 602 F.3d 1325, 1337 (Fed. Cir. 2010). Thus, the “very essence of inherency is that one of ordinary skill in the art would recognize that a reference unavoidably teaches the property in question.” Agilent Technologies, Inc. v. Affymetrix, Inc., 567 F.3d 1366, 1383 (Fed. Cir. 2009) (emphasis added).” slip op. at 23
Claim construction§ 102 anticipation§ 112 disclosureDiscretionary denialcites PhillipsPatents in suitUS 11,007,201 - PTAB · Dec 1, 2023 · PGR2021-00088 · APJ John G New · PGR · Remand
The Board instituted PGR on claims 1–25 on all five grounds, finding the threshold met based on likely anticipation, obviousness, and lack of written-description support.
RulingsRemand decision- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted
“Under 35 U.S.C. § 324, the Board “may not authorize a post-grant review to be instituted unless … the information presented in the petition … if such information is not rebutted would demonstrate that it is more likely than not that at least 1 of the claims challenged in the petition is unpatentable.” In conformance with the Director’s Decision, and for the reasons we explain herein, we institute post-grant review of the ’908 patent.” slip op. at 2
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed board ownDecided for petitioner
“The Specification expressly teaches that, with respect to the clinical phase 2 trial described in Example 4, “Patients will have overnight [pharmacokinetic/pharmacodynamics] PK/PD assessments performed at baseline, which include an [sic] pre-dose overnight assessment and a post-dose overnight assessment for PK/PD following administration of the first dose.” Ex. 1001, col.42, ll. 12–16. This is the same quotation and clinical trial relied upon by Dr. Barnes in his Declaration, and is the only definition of a “baseline” in the ’908 patent. See Ex. 1002, 36–37. We note that placebos were evidently not employed in the phase 2 clinical study of Example 4.3 Given the sole exemplary description of “baseline” in Example 4 of the Specification, we construe the claim term reciting “reduced by at least 10% from baseline” as meaning “a reduction of at least 10% in the level of ACTH (claim 1) or 17-OHP (claim 11) compared to measurements of ACTH or 17-OHP made prior to, and/or at the beginning of, administration of the drug.”” slip op. at 10
- Skill levelSkill level petitioner adoptedDecided for petitioner
“Petitioner contends that a person of ordinary skill in the art would typically possess a medical degree or a Ph.D. in a field related to endocrinology, and would have knowledge of hormone regulation and disorders, as well as knowledge of the treatment regimens employed to treat such disorders. Pet. 60 (citing Ex. 1005 ¶ 34). Petitioner argues that such a person of ordinary skill would also have at least three years of experience conducting research concerning endocrine disorders, including CAH or other adrenal disorders. Id. Patent Owner does not expressly contest this definition of a person of ordinary skill in the art in its Preliminary Response. For the purposes of this Decision, because we find Petitioner’s definition to be consistent with the demonstrable level of skill in the art (see, e.g., Exs. 1009, 1025, 2003, 2004,” slip op. at 11
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element) › Inherent disclosureInherency foundInstituted
“A claim is unpatentable as anticipated under 35 U.S.C. § 102 only when “every element and limitation of the claim was previously described in a single prior art reference, either expressly or inherently, so as to place a person of ordinary skill in possession of the invention.” Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1082 (Fed. Cir. 2008). A reference may inherently anticipate if a claim limitation that is not expressly disclosed “is necessarily present, or inherent, in the single anticipating reference.” Verizon Servs. Corp. v. Cox Fibernet Va., Inc., 602 F.3d 1325, 1337 (Fed. Cir. 2010). Thus, the “very essence of inherency is that one of ordinary skill in the art would recognize that a reference unavoidably teaches the property in question.” Agilent Technologies, Inc. v. Affymetrix, Inc., 567 F.3d 1366, 1383 (Fed. Cir. 2009) (emphasis added).” slip op. at 23
Claim construction§ 102 anticipation§ 103 obviousness§ 112 disclosureDiscretionary denialcites PhillipsPatents in suitUS 10,849,908 - Kioxia Corporation / Kioxia America, Inc. v. Viasat, Inc.No claims unpatentablePTAB · Nov 20, 2023 · IPR2022-01067 · APJ Elizabeth M Roesel · IPR · Final written decision
Claims 1–4, 8, 10–19, and 23–25 were not shown unpatentable because the cited art did not disclose the claimed decoding and forwarding functions, and the proposed modifications were not adequately supported.
RulingsFinal written decision- Skill levelSkill level patent owner adoptedDecided for patent owner
“similar, and we adopt parts of each party’s description of a POSITA’s education and experience. We agree with Patent Owner that computer engineering and computer science are relevant fields of study. PO Resp. 3. Our finding is supported by the ’700 Patent, which describes systems, devices, methods, and software for forward error correction for a flash memory system, which may be integrated with a computer, server, or other computing device. Ex. 1001, 3:23–30. Although Dr. Koralek testifies that an undergraduate education would not have been sufficient for a person to acquire ordinary skill in the art relating the ’700 Patent (Ex. 1024 ¶¶ 7–9), that testimony does not adequately account for the knowledge relating to error correction a person could acquire through practical experience. For this reason, we agree with Patent Owner and Dr. Bagherzadeh that a bachelor of science is the appropriate level of education. PO Resp. 3; Ex. 2022 ¶ 31. We disagree with Patent Owner’s assertion that a POSITA’s experience would have been limited to “hardware implementation.” PO Resp. 3. Our finding is supported by the ’700 Patent, which states that “embodiments may be implemented by hardware, software, firmware, middleware, microcode, hardware description languages, or any combination thereof.” Ex. 1001, 10:26–28. For these reasons, we find that a POSITA would have had a bachelor of science degree in electrical engineering, computer engineering, computer science, or a related field, and two years of academic or industry experience in the design, development, or research of error correction in memory devices.” slip op. at 11
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Term construed board ownDecided for patent owner
“mentioned in the Specification. In each instance, buffering is disclosed along with de-interleaving and decoding as actions performed by a decoder module or sub-module. The Specification’s disclosure that a decoder module can buffer data does not mean that buffering alone can constitute decoding. Nowhere does the Specification define “decode” to mean just “buffer.” The Specification’s use of the disjunctive, “or,” to connect these words (Ex. 1001, 6:11–14) is not enough to redefine the word “decode” to encompass buffering alone. Petitioner agrees that “[t]he ’700 Patent does not define the word ‘decode.’” Pet. Reply 2. “Absent lexicography or disavowal, we do not depart from the plain meaning of the claims.” Luminara Worldwide, LLC v. Liown Elecs. Co., 814 F.3d 1343, 1353 (Fed. Cir. 2016) (citing Thorner v. Sony Computer Entm't Am. LLC, 669 F.3d 1362, 1365 (Fed. Cir. 2012)). “The standards for finding lexicography and disavowal are ‘exacting.’” Id. (quoting GE Lighting Sols., LLC v. AgiLight, Inc., 750 F.3d 1304, 1309 (Fed. Cir. 2014)). In this case, defining “decode” to encompass mere buffering would be a departure from the plain and ordinary meaning of the term as understood by a POSITA. Petitioner’s expert, Dr. Koralek, agrees that, “aside from the ’700 patent, what a person of ordinary skill would understand decode to mean, it would not be just buffering. Decoding might include buffering, but buffering by itself would not be considered decoding to a person of ordinary skill.” Ex. 2023, 73:14–20. As Petitioner recognizes, “it is undisputed that ‘decoding’ is the opposite of ‘encoding.’” Pet. Reply 7 (citing Ex. 1019, 56:5–11); see also PO Resp. 7 (“The plain meaning of ‘decode’ implies undoing or reversing some prior encoding.”). This undisputed meaning is supported by the expert testimony, as well as dictionary definitions provided” slip op. at 14
- Strike new argumentNew argument disregardedDecided for patent owner
“ECC bits on a page-level rather than by sector was known before the ’700 Patent” and relies on Dr. Koralek’s opinion that “page-level encoding would have been an obvious implementation in view of Lee’s teachings.” Pet. Reply 4; Ex. 1024 ¶ 45. Petitioner’s contention presents a new theory of unpatentability based on new evidence11 that exceeds the proper scope of a reply brief under 37 C.F.R. § 42.23(b). For that reason, we need not consider it.12 Petitioner’s contention is not persuasive in any event. The challenge before us is anticipation, not obviousness. Petitioner’s new theory is not enough to show that Lee “must necessarily” distinguish error correction bits from information bits in the received encoded data, as asserted in the Petition (Pet. 22) and required by our claim construction. 11 The new evidence includes Exhibit 1021 and paragraphs 45 to 47 of Dr. Koralek’s supplemental testimony, Exhibit 1024. 12 Yita LLC v. MacNeil IP LLC, 69 F.4th 1356, 1366–67 (Fed. Cir. 2023) (stating “the Board acts within its discretion when it declines under section 42.23(b) to consider a new theory of unpatentability raised for the first time in reply” and holding that petitioner’s reply argument that a claim limitation would have been an obvious modification was a “meaningfully distinct contention” from the petition’s argument that the limitation was taught by the reference and that the new theory was not within the scope of a proper reply); Intelligent Bio-Sys., Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359, 1369–70 (Fed. Cir. 2016) (affirming Board’s decision not to consider an argument made on reply because in the original petition the challenger argued only that a reference disclosed a limitation, while in the reply the challenger argued that a relevant artisan would have considered it obvious to modify that reference to arrive at the limitation).” slip op. at 23
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)Not shown unpatentableNot shown unpatentable
“As discussed above, we construe the phrase, “decode the received encoded data,” to mean “distinguish error correction bits from information bits in the received encoded data.” We are not persuaded by Petitioner’s contention that Lee’s page buffer 504 performs this function. Pet. 22. Petitioner identifies Lee’s page buffer 504 as the “decoding module” of claim 1 (Pet. 20–21), but does not show that page buffer 504 decodes the received encoded data by distinguishing error correction bits from information bits in the received encoded data.” slip op. at 21
Patent outcomesUS 8,615,700 not shown unpatentableClaim construction§ 102 anticipation§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 8,615,700 - Western Digital Technologies, Inc. / Kioxia Corporation et al. v. Viasat, Inc.Some claims unpatentablePTAB · Nov 20, 2023 · IPR2023-00408 · APJ Elizabeth M Roesel · IPR · Final written decision
Claims 1, 4, 8, 15, 17, and 19 are unpatentable as anticipated by Wu; claim 2 was not shown unpatentable under the Jo-Wu or Jo-Wan obviousness grounds.
RulingsFinal written decision- Skill levelSkill level patent owner adoptedDecided for patent owner
“The parties’ articulations of the level of ordinary skill in the art are similar, and we adopt parts of each party’s description of a POSITA’s education and experience. We agree with Patent Owner that computer engineering is a relevant field of study. PO Resp. 3. Our finding is supported by the ’700 Patent, which describes systems, devices, methods, and software for forward error correction for a flash memory system, which may be integrated with a computer, server, or other computing device. Ex. 1001, 3:23–30. We adopt Patent Owner’s proposal regarding the length of a POSITA’s practical experience—two years—rather than four years, as proposed by Petitioner. Neither Petitioner nor Dr. Dolecek assert that two years of practical experience would have been insufficient to acquire POSITA’s experience would have been limited to “hardware implementation.” PO Resp. 3. Our finding is supported by the ’700 Patent, which states that “embodiments may be implemented by hardware, software, firmware, middleware, microcode, hardware description languages, or any combination thereof.” Ex. 1001, 10:26–28. Petitioner’s assertion that a POSITA needs to have experience in “error correction coding (‘ECC’) systems (which include forward error correction or ‘FEC’systems)” (Pet. 19; Ex. 1003 ¶ 25) is consistent with the ’700 Patent, which discloses methods, systems, and devices for forward error correction for flash memory. Ex. 1001, code (57); see also Ex. 1003 ¶¶ 57, 66 (explaining that error correction coding (“ECC”) includes forward error correction (“FEC”)). For these reasons, we find that a POSITA would have had a bachelor of science degree in electrical engineering, computer engineering, or computer science or a related field, and two years of experience designing, developing, or researching error correction coding systems, which include forward error correction systems.” slip op. at 9
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction needed
“The Board is required to construe ‘only those terms . . . that are in controversy, and only to the extent necessary to resolve the controversy.” Realtime Data, LLC v. Iancu, 912 F.3d 1368, 1375 (Fed. Cir. 2019) (quoting Vivid Techs., Inc. v. Am. Sci. Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999))). Neither party seeks express constructions of any claim terms. See Pet. 20; see generally PO Resp. We do not need to provide an express construction for any claim terms for purposes of resolving the controversy before us. slip op. at 11
- Expert testimonyPetitioner expert creditedPatent owner expert discountedDecided for petitioner
“We find that Dr. Dolecek’s testimony about Wu’s Figure 8 and a “plurality of data streams” is more credible than Dr. Bagherzadeh’s testimony on this topic. Dr. Bagherzadeh testifies that Wu’s scrambler “does not split, copy, or otherwise ‘generate a plurality of partially decoded data streams.’” Id. ¶¶ 100, 108. But that testimony fails to take into account what the depiction of multiple double-sided arrows in Wu’s Figure 8 would have meant to a POSITA, as Dr. Dolecek testifies. Ex. 1003 ¶ 86 (reproducing Wu’s Figure 8 with double-headed arrows between ECC engines 822-0 to 822-M and scrambler 103 shaded yellow to identify a “plurality of partially decoded data streams”). The evidence does not support Dr. Bagherzadeh’s opinion that Wu’s Figure 8 is “incompatible” with Wu’s description and “there’s no way to generate a plurality of data streams from the Scrambler to the ECC Engines.” Ex. 2023 ¶ 109. As Dr. Dolecek explained below, when viewed through the eyes of a POSITA, Wu discloses that the scrambler can generate a plurality of data streams.” slip op. at 18
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)UnpatentableUnpatentable
“arrows between scrambler 103 and ECC Engines 822-0 to 822-M in Wu’s Figure 8 is sufficient to disclose the generation of a plurality of data streams, as claimed. Pet. 36–37; Pet. Reply 2–6. As between Petitioner’s position that the multiple arrows in Wu’s Figure 8 represent multiple data streams (Pet. 36–37; Pet. Reply 2–3), and Patent Owner’s position that “those arrows are not meant to be taken literally as literal data streams” (Tr. 35:16–17), we find that Petitioner’s position is more reasonable, consistent with the legal standard for anticipation, and amply supported in the record. “In an anticipation analysis, the dispositive question is whether a skilled artisan would ‘reasonably understand or infer’ from a prior art reference that every claim limitation is disclosed in that single reference.” Acoustic Tech., Inc. v. Itron Networked Sols., Inc., 949 F.3d 1366, 1373 (Fed. Cir. 2020) (citing Akamai Techs., Inc. v. Cable & Wireless Internet Servs., Inc., 344 F.3d 1186, 1192 (Fed. Cir. 2003)). “Expert testimony may shed light on what a skilled artisan would reasonably understand or infer from a prior art reference.” Id. (citing Monsanto Tech. LLC v. E.I. DuPont de Nemours & Co., 878 F.3d 1336, 1345 (Fed. Cir. 2018)).” slip op. at 17
Patent outcomesUS 8,615,700 mixedClaim construction§ 102 anticipation§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 8,615,700 - Western Digital Technologies, Inc. / Kioxia Corporation et al. v. Viasat, Inc.Some claims unpatentablePTAB · Nov 20, 2023 · IPR2022-01126 · APJ Elizabeth M Roesel · IPR · Final written decision
Claims 1, 4, 8, 15, 17, and 19 are unpatentable as anticipated by Wu; claim 2 was not shown unpatentable under the asserted obviousness grounds.
RulingsFinal written decision- PTAB / AIA Trials › Joinder §315(c) / SAS all-or-nothingJoinder, grantedGranted
“1 Kioxia Corporation and Kioxia America, Inc. filed a petition and a motion for joinder in IPR2023-00408 and have been joined as petitioners to this proceeding. INTRODUCTION A. Background and Summary Western Digital Technologies, Inc. (“Petitioner”) filed a Petition (Paper 1, “Pet.”) seeking an inter partes review of claims 1, 2, 4, 8, 15, 17, and 19 (the “challenged claims”) of U.S. Patent No. 8,615,700 B2 (Ex. 1001, “the ’700 Patent”). Viasat, Inc. (“Patent Owner”) filed a Preliminary Response. Paper 12 (“Prelim. Resp.”). We instituted an inter partes review. Paper 13 (“Institution Decision” or “Inst. Dec.”). Kioxia Corporation and Kioxia America, Inc. (collectively, “Kioxia”) filed a substantively identical petition, and we granted institution and joined Kioxia as a petitioner to this proceeding. Paper 25 (copy of Paper 9 from IPR2023-00408).” slip op. at 1
- Skill levelSkill level patent owner adoptedDecided for patent owner
“The parties’ articulations of the level of ordinary skill in the art are similar, and we adopt parts of each party’s description of a POSITA’s education and experience. We agree with Patent Owner that computer engineering is a relevant field of study. PO Resp. 3. Our finding is supported by the ’700 Patent, which describes systems, devices, methods, and software for forward error correction for a flash memory system, which may be integrated with a computer, server, or other computing device. Ex. 1001, 3:23–30. We adopt Patent Owner’s proposal regarding the length of a POSITA’s practical experience—two years—rather than four years, as proposed by Petitioner. Neither Petitioner nor Dr. Dolecek assert that two years of practical experience would have been insufficient to acquire POSITA’s experience would have been limited to “hardware implementation.” PO Resp. 3. Our finding is supported by the ’700 Patent, which states that “embodiments may be implemented by hardware, software, firmware, middleware, microcode, hardware description languages, or any combination thereof.” Ex. 1001, 10:26–28. Petitioner’s assertion that a POSITA needs to have experience in “error correction coding (‘ECC’) systems (which include forward error correction or ‘FEC’systems)” (Pet. 19; Ex. 1003 ¶ 25) is consistent with the ’700 Patent, which discloses methods, systems, and devices for forward error correction for flash memory. Ex. 1001, code (57); see also Ex. 1003 ¶¶ 57, 66 (explaining that error correction coding (“ECC”) includes forward error correction (“FEC”)). For these reasons, we find that a POSITA would have had a bachelor of science degree in electrical engineering, computer engineering, or computer science or a related field, and two years of experience designing, developing, or researching error correction coding systems, which include forward error correction systems.” slip op. at 9
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)UnpatentableUnpatentable
“arrows between scrambler 103 and ECC Engines 822-0 to 822-M in Wu’s Figure 8 is sufficient to disclose the generation of a plurality of data streams, as claimed. Pet. 36–37; Pet. Reply 2–6. As between Petitioner’s position that the multiple arrows in Wu’s Figure 8 represent multiple data streams (Pet. 36–37; Pet. Reply 2–3), and Patent Owner’s position that “those arrows are not meant to be taken literally as literal data streams” (Tr. 35:16–17), we find that Petitioner’s position is more reasonable, consistent with the legal standard for anticipation, and amply supported in the record. “In an anticipation analysis, the dispositive question is whether a skilled artisan would ‘reasonably understand or infer’ from a prior art reference that every claim limitation is disclosed in that single reference.” Acoustic Tech., Inc. v. Itron Networked Sols., Inc., 949 F.3d 1366, 1373 (Fed. Cir. 2020) (citing Akamai Techs., Inc. v. Cable & Wireless Internet Servs., Inc., 344 F.3d 1186, 1192 (Fed. Cir. 2003)). “Expert testimony may shed light on what a skilled artisan would reasonably understand or infer from a prior art reference.” Id. (citing Monsanto Tech. LLC v. E.I. DuPont de Nemours & Co., 878 F.3d 1336, 1345 (Fed. Cir. 2018)).” slip op. at 17
- Expert testimonyPetitioner expert creditedPatent owner expert discountedDecided for petitioner
“We find that Dr. Dolecek’s testimony about Wu’s Figure 8 and a “plurality of data streams” is more credible than Dr. Bagherzadeh’s testimony on this topic. Dr. Bagherzadeh testifies that Wu’s scrambler “does not split, copy, or otherwise ‘generate a plurality of partially decoded data streams.’” Id. ¶¶ 100, 108. But that testimony fails to take into account what the depiction of multiple double-sided arrows in Wu’s Figure 8 would have meant to a POSITA, as Dr. Dolecek testifies. Ex. 1003 ¶ 86 (reproducing Wu’s Figure 8 with double-headed arrows between ECC engines 822-0 to 822-M and scrambler 103 shaded yellow to identify a “plurality of partially decoded data streams”). The evidence does not support Dr. Bagherzadeh’s opinion that Wu’s Figure 8 is “incompatible” with Wu’s description and “there’s no way to generate a plurality of data streams from the Scrambler to the ECC Engines.” Ex. 2023 ¶ 109. As Dr. Dolecek explained below, when viewed through the eyes of a POSITA, Wu discloses that the scrambler can generate a plurality of data streams. After quoting from Dr. Dolecek’s deposition testimony (Ex. 2023 ¶ 107 (quoting Ex. 2024, 32:15–22)), Dr. Bagherzadeh asserts that “Dr. Dolecek does not explain how she believes the intra-channel operation of the Scrambler on the ‘one long data stream’ it receives could generate a account Dr. Dolecek’s testimony in response to follow-up questions from Patent Owner. Q So you have found the plurality of data streams in the three arrows of Figure 8 going from the scrambler to the ECC engines? A Yes. . . . Q And how exactly, in your understanding as a person of skill, does the scrambler generate that plurality? . . . THE WITNESS: . . . So the person of ordinary skill in the art would understand that these are multiple arrows here indicated explicitly to suggest parallel operations of the ECC engines. And for them to have parallel operations, a person of ordinary skill in the art would assume that they are receiving inputs at the same time, and the scrambler would, for example, do that by sending descrambled data to different engines at a time, one at a time. . . . Q So how does the scrambler’s function of intrachannel rearrangement generate multiple data streams? . . . THE WITNESS: Once it’s descrambled on a per-block basis, it simply sends that block to a given engine, ECC engine. . . . Q Can the scrambler send out multiple data streams in parallel at the same time? A If it’s designed like that, yes. Ex. 2024, 32:24–34:7 (objections and witness’s false start omitted). Q So describe for me how in Figure 8 that would work for your analysis where the scrambler receiving the data from the multiplexer would then generate the plurality of partially decoded data streams. A Right. Figure 8. So if it receives a long string of data that has already been processed by the 104 unit, it would perform intra- -- intrachannel, if you will, intrablock disarrangement of data. And then it could” slip op. at 18
Patent outcomesUS 8,615,700 mixedClaim construction§ 102 anticipation§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 8,615,700 - PTAB · Nov 15, 2023 · IPR2023-00821 · APJ Stephen E Belisle · IPR · Institution
The Board instituted review of claims 1–20 on all petition grounds, finding a reasonable likelihood that claims 1 and 3 are anticipated by Jones and claims 1–20 are obvious over Jones, Zheng, and Keenan.
RulingsInstitution decision- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted
“review. 35 U.S.C. § 314(b) (2018); 37 C.F.R. § 42.4(a) (2022). We may not institute an inter partes review “unless . . . there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). The “reasonable likelihood” standard is “a higher standard than mere notice pleading” but “lower than the ‘preponderance’ standard to prevail in a final written decision.” Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, Paper 29 at 13 (PTAB Dec. 20, 2019) (precedential). When instituting inter partes review, the Board will authorize the review to proceed on all of the challenged claims and on all grounds of unpatentability asserted for each claim. 37 C.F.R. § 42.108(a). Applying those standards, and upon consideration of the information presented in the Petition and Preliminary Response, we determine that Petitioner has demonstrated a reasonable likelihood of success in proving that at least one claim of the ’008 patent is unpatentable. See 35 U.S.C. § 314; 37 C.F.R. § 42.4(a). Accordingly, we institute an inter partes review” slip op. at 2
- Skill levelSkill level petitioner adoptedDecided for petitioner
“In determining the level of ordinary skill in the art, various factors may be considered, including the “type of problems encountered in the art; prior art solutions to those problems; rapidity with which innovations are made; sophistication of the technology; and educational level of active workers in the field.” In re GPAC Inc., 57 F.3d 1573, 1579 (Fed. Cir. 1995) (citation omitted). The level of ordinary skill in the art also is reflected by the prior art of record. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001). Neither party argues, at least at this stage of the proceeding, that the outcome of this case would differ based on our adoption of any particular definition of the level of ordinary skill in the art. Considering the subject matter of the ’008 patent, the background technical field, the prior art, and Petitioner’s proposed and unopposed definition of the skilled artisan, we apply the level of skill set forth above, which is consistent with the testimony of Mr. Hurlbut (Ex. 1003 ¶ 33).” slip op. at 13
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededNot reached
“Only those claim terms that are in controversy need to be construed, and only to the extent necessary to resolve the controversy. See Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., 868 F.3d 1013, 1017 (Fed. Cir. 2017) (stating that “we need only construe terms ‘that are in controversy, and only to the extent necessary to resolve the controversy’” (quoting Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999))). Petitioner proffers constructions for two terms, namely, (1) “threat model components” and (2) “attack paths,” as recited, for example, in independent claim 4. Pet. 12. Petitioner submits that it defines these two terms “consistent with the ’008 patent specification and applies the plain and ordinary meaning that [the skilled artisan] would attribute to the remaining terms.” Pet. 12. “Patent Owner submits that the Board need not engage in any pre-institution claim construction of these [two] terms.” Prelim. Resp. 11. Based upon our consideration of the record at this stage of the proceeding, we conclude that it is unnecessary to interpret expressly any term in the ’008 patent claims for which we institute inter partes review. See Nidec, 868 F.3d at 1017. Nevertheless, we determine that briefing during the trial on the proper interpretation of certain claim terms may assist us in resolving issues presented in this case. In particular, we invite the parties to address the proper construction of the limitation “redefine the first threat model by including in it a second threat model associated with the component group,” as recited, for example, in independent claim 1, and to provide evidentiary support therefor (the parties should focus particularly on defining the full scope of what it means to “redefine” the first threat model and to “include” a second threat model “in” a first threat model). To the extent that a party proposes that this limitation should have its ordinary and customary meaning, we encourage the party to explicitly identify such meaning(s) and the evidentiary support therefor. In addition, the parties should consider whether Ex parte Schulhauser, No. 2013-007847, 2016 WL 6277792 (PTAB Apr. 28, 2016) (precedential) applies to limitations of the challenged claims, such as claim 1’s recital of “configuring the diagram interface to, in response to receiving one or more user inputs, add a component group to the first threat model.”” slip op. at 15
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)Instituted
“Pet. 35–36 (emphases added) (citing Ex. 1004, 6:12–34; Ex. 1003 ¶¶ 81–84). As we understand Petitioner’s argument (and its expert’s testimony), Petitioner argues Jones “modifies,” i.e., “redefines,” a “first threat model” (level n) by “including” in it cybersecurity threats (e.g., via metadata) associated with nested components (i.e., “a second threat model”), to produce the “modified” (“redefined”) “first threat model” (level n+1). See id.; In re Bond, 910 F.2d at 832–33 (anticipation “is not an ‘ipsissimis verbis’ test”). In other words, Petitioner argues that, although Jones may not use the identical terminology as the ’008 patent, Jones nevertheless explicitly discloses limitation 1[f] to the skilled artisan, by describing modifying a first “threat” model from a level “n” model to a level “n+1” model by including therein threats associated with a particular layer of components (nested components), i.e., a second “threat” model. Based on the record before us, we find Petitioner’s arguments persuasive.” slip op. at 22
Claim construction§ 102 anticipation§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 10,699,008 - PTAB · Oct 6, 2023 · IPR2023-00656 · APJ Stephen E Belisle · IPR · Institution
The Board instituted IPR on claims 1–20 and all petition grounds, finding a reasonable likelihood that Keenan anticipates the claims.
RulingsInstitution decision- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted
“review. 35 U.S.C. § 314(b) (2018); 37 C.F.R. § 42.4(a) (2022). We may not institute an inter partes review “unless . . . there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). The “reasonable likelihood” standard is “a higher standard than mere notice pleading” but “lower than the ‘preponderance’ standard to prevail in a final written decision.” Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, Paper 29 at 13 (PTAB Dec. 20, 2019) (precedential). When instituting inter partes review, the Board will authorize the review to proceed on all of the challenged claims and on all grounds of unpatentability asserted for each claim. 37 C.F.R. § 42.108(a). Applying those standards, and upon consideration of the information presented in the Petition and Preliminary Response, we determine that Petitioner has demonstrated a reasonable likelihood of success in proving that at least one claim of the ’366 patent is unpatentable. See 35 U.S.C. § 314; 37 C.F.R. § 42.4(a). Accordingly, we institute an inter partes review as to all Challenged Claims of the ’366 patent on all grounds raised in the Petition.” slip op. at 2
- Skill levelSkill level petitioner adoptedDecided for petitioner
“B. Level of Ordinary Skill in the Art Petitioner contends that a person of ordinary skill in the art, at the time of the earliest effective filing date of the ’366 patent: would have had a Bachelor’s degree in computer engineering, computer science, mathematics, or a similar discipline, with at least three years of relevant industry or research experience, including experience in software development and designing or implementing threat models. Additional work or research” slip op. at 9
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther
“Only those claim terms that are in controversy need to be construed, and only to the extent necessary to resolve the controversy. See Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., 868 F.3d 1013, 1017 (Fed. Cir. 2017) (stating that “we need only construe terms ‘that are in controversy, and only to the extent necessary to resolve the controversy’” (quoting Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999))). Petitioner proffers constructions for four terms, namely, (1) “third party software application,” (2) “third party diagram components,” (3) “visual representations of the threat model components,” and (4) “threat model components,” each as recited, for example, in independent claim 1. Pet. 12–14. Petitioner submits “[Patent Owner] defined [these] claim terms in the specification and file history,” “Petitioner is applying those definitions in this petition,” and “[f]or all other claim terms, Petitioner applies the plain and ordinary meaning that a [skilled artisan] would attribute to those terms.” Pet. 12. “Patent Owner submits that the Board need not engage in any pre-institution claim construction of these [four] terms.” Prelim. Resp. 11. Based upon our consideration of the record at this stage of the proceeding, we conclude that it is unnecessary to interpret expressly any term in the ’366 patent claims for which we institute inter partes review. See Nidec, 868 F.3d at 1017. Nevertheless, we determine that briefing during the trial on the proper interpretation of certain claim terms may assist us in resolving issues presented in this case. In particular, we invite the parties to address the proper construction of “threats,” “threat model components,” “visual representations of the threat model components,” and “mapping files,” and the evidentiary support therefor. To the extent that a party proposes that such a term should have its ordinary and customary meaning, we encourage the party to explicitly identify such meaning(s) and the evidentiary support therefor.” slip op. at 11
- Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)Instituted
“does not disclose the “threats” described and claimed in the ’366 patent. See Prelim. Resp. 5–7, 11–19. Based on the record before us at this stage of the proceeding, we disagree and preliminarily find Patent Owner’s arguments unavailing, as further discussed below. In particular, Patent Owner concedes that “Keenan discloses that color can ‘represent different types of risk (e.g., cyber, environmental, accidental, etc.),’” where Keenan displays such colors associated with objects in a topology. Prelim. Resp. 17 (citing Ex. 1004, 16:40–51) (emphases added); see Ex. 1004, Fig. 7. But Patent Owner then merely concludes, without citing any factual support, that “use of a color identifying the generic nature of a risk still fails to disclose any threats associated with the risk.” Id. at 17– 18. On the other hand, Petitioner’s expert, Mr. Hurlbut, testifies: Keenan demonstrates that its risk measurement and display includes a determination of threats where Keenan discloses a risk measurement view that uses [] color to “represent different types of risk (e.g., cyber, environmental, accidental, etc.).” [Ex. 1004], 16:40–51. [The skilled artisan] would understand that “types of risk,” as disclosed in Keenan are threats because the described examples are all types of threats (cyber, environmental, accidental). Thus, Keenan discloses threats within its risk analysis. Moreover, [the skilled artisan] would understand that risk is a function of threats exploiting vulnerabilities to obtain, damage, or destroy assets. In other words, threat modeling is used to identify risk. Ex. 1003 ¶ 79 (cited at Pet. 21–24); see id. ¶ 82 (cited at Pet. 26–28). Patent Owner disputes this testimony of Mr. Hurlbut using only attorney argument, and without telling us, for example, why Mr. Hurlbut allegedly is wrong (e.g., by explaining why specific “types” of risk do not fall within the scope of “threats” as broadly recited in claim 1, or how “risk” is not a function of “threats” in Keenan, as explained by Mr. Hurlbut). See In re Pearson, 494 F.2d 1399, 1405 (CCPA 1974) (“Attorney’s argument in a brief cannot take the place of evidence.”). Moreover, although Patent Owner characterizes the “types of risk” disclosed in Keenan as identifying a “generic nature of a risk” (Prelim. Resp. 17–18 (emphasis added)), we note that “threats” is broadly recited in claim 1 with no requirement as to any level of specificity of such threats.” slip op. at 18
Claim construction§ 102 anticipation§ 103 obviousnesscites Phillips · KSR · GrahamPatents in suitUS 10,713,366
Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.